Cephalexin sodium
Based on 10 publication(s) in Google Scholar
Cephalexin sodium is an orally active cephalosporin Antibiotic. Cephalexin sodium disrupts bacterial cell wall synthesis and inhibits the growth of susceptible Gram-positive bacteria and some Gram-negative bacteria. Cephalexin sodium induces acute renal failure when overdosed in laboratory animals. Cephalexin sodium can be used in studies related to bacterial infections.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 38932-40-0
- 화학식: C16H16N3NaO4S
- 분자량:369.37
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Cephalexin sodium
More- Theranostics. 2022 Jan 1;12(3):1187-1203. [Abstract]
- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- J Med Chem. 2021 Oct 14;64(19):14344-14357. [Abstract]
- PLoS Pathog. 2026 Jul 16;22(7):e1014242.
- Infect Immun. 2018 May 22;86(6):e00090-18. [Abstract]
- Biomed Res Int. 2018 Jul 2:2018:3579832. [Abstract]
- University of Texas. 2025.
- bioRxiv. 2024 May 10.
- Chemosphere. 2021 Dec:285:131417. [Abstract]
- Chemosphere. 2019 Jun:225:378-387. [Abstract]
All Antibiotic Isoforms
More
Biological Activity
제품 설명
In Vitro
Cephalexin (30 μg per disc) sodium exhibits in vitro activity against most indole-negative Proteus sp., Escherichia coli, Salmonella sp., Shigella sp., and Paracolobactrum sp. strains, but no activity against indole-positive Proteus sp., Pseudomonas sp., or Alcaligenes sp., and partial activity against Klebsiella-Aerobacter spp. when tested via 30-μg disc assay[3].
Cephalexin (15-30 μg per disc) sodium potently inhibits most gram-positive bacteria and Neisseria sp. in vitro, with MIC values ranging from 0.16 μg/mL (Neisseria meningitidis strain Suederlin) to 200 μg/mL (Streptococcus sp. group D strain 9960), and disc-plate zones of inhibition correlating with tube dilution sensitivity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Cephalexin (<10->166 mg/kg; p.o.; two doses at 1 and 5 hours post-infection) exhibits in vivo efficacy against a range of experimental gram-negative bacterial infections in mice, with ED50 values ranging from <10 mg/kg to >166 mg/kg depending on the bacterial strain[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:McAllister strain (11 to 13 g)[3]
-
Dosage:Not specified
-
Administration:p.o.; two doses at 1 and 5 hours post-infection
-
Result:Achieved an oral ED50 of 1.15 mg/kg against penicillin-sensitive S. aureus strain 3055.
Achieved an oral ED50 of 3.7 mg/kg against penicillin-resistant S. aureus strain 3074.
Achieved an oral ED50 of 1.8 mg/kg against Streptococcus pyogenes strain C203.
Achieved an oral ED50 of 58.2 mg/kg against Diplococcus pneumoniae Type I.
-
Animal Model:McAllister strain (11 to 13 g)[3]
-
Dosage:Not specified
-
Administration:p.o.; two doses at 1 and 5 hours post-infection
-
Result:Achieved an oral ED50 of 22.1 mg/kg against indole-negative Proteus sp. strain PR-4.
Achieved oral ED50 values >166 mg/kg against indole-positive Proteus sp. strains PR-9 and PR-15.
Achieved an oral ED50 of 18.9 mg/kg against Salmonella typhosa strain SA-12.
Achieved an oral ED50 of <10 mg/kg against Shigella flexneri 2b strain SH-3.
Achieved an oral ED50 of 5.2 mg/kg against Klebsiella-Aerobacter spp. strain KA-14.
Achieved an oral ED50 of 166 mg/kg against Klebsiella-Aerobacter spp. strain KA-17.
Achieved an oral ED50 of 11.7 mg/kg against Escherichia coli strain EC-14.
Achieved an oral ED50 >166 mg/kg against Escherichia coli strain EC-17.
Achieved an oral ED50 <10 mg/kg against Escherichia coli strain EC-38.
Chemical Information
-
CAS No. 38932-40-0
-
분자량 369.37
-
화학식 C16H16N3NaO4S
-
SMILES
O=C1N2[C@@](SCC(C)=C2C(O[Na])=O)([H])[C@@H]1NC([C@@H](C3=CC=CC=C3)N)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Theranostics
Antibiotic Azithromycin inhibits brown/beige fat functionality and promotes obesity in human and rodents. [Abstract]2022 Jan 1;12(3):1187-1203. PMID: 35154482 -
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
J Med Chem
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors. [Abstract]2021 Oct 14;64(19):14344-14357. PMID: 34547896 -
-
Infect Immun
Identification and Characterization of the Neisseria gonorrhoeae MscS-Like Mechanosensitive Channel. [Abstract]2018 May 22;86(6):e00090-18. PMID: 29581189 -
Biomed Res Int
In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates. [Abstract]2018 Jul 2:2018:3579832. PMID: 30065936 -
-
-
Chemosphere
Insights into the degradation mechanisms and pathways of cephalexin during homogeneous and heterogeneous photo-Fenton processes. [Abstract]2021 Dec:285:131417. PMID: 34246101 -
Chemosphere
Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]2019 Jun:225:378-387. PMID: 30884299
순도&문서
References
[3]. Wick WE. Cephalexin, a new orally absorbed cephalosporin antibiotic. Applied microbiology. 1967 Jul;15(4):765-9. [Content Brief]
[4]. Lode H, et al. Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrobial agents and chemotherapy. 1979 Jul;16(1):1-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cephalexin sodium Related Classifications
HY-W747255 Related Classifications
Powered by Bioz